C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
Andrea Bild,Andrea Bild,Joel S. Parker,Adam M. Gustafson,Chaitanya R. Acharya,Katherine A. Hoadley,Carey K. Anders,P. Kelly Marcom,Lisa A. Carey,Anil Potti,Joseph R. Nevins,Charles M. Perou +11 more
TL;DR: An integrated analysis of breast cancer is used that combines independent methods of genomic analyses to highlight the complexity of signaling pathways underlying different breast cancer phenotypes and to identify optimal therapeutic opportunities.
Journal ArticleDOI
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
M. Martin,Atocha Romero,Maggie C.U. Cheang,J. A. Lopez Garcia-Asenjo,José A. García-Sáenz,B. Oliva,J.M. Roman,Xiaping He,Antonio Casado,J. de la Torre,V. Furio,Javier Puente,Trinidad Caldés,J.A. Vidart,Sara López-Tarruella,Sara López-Tarruella,Eduardo Díaz-Rubio,Charles M. Perou +17 more
TL;DR: Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER/PgR/HER2 negative status predicted response to docetaxel.
Journal ArticleDOI
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium
Justin M. Balko,Todd W. Miller,Meghan M. Morrison,Katherine E. Hutchinson,Christian D. Young,Cammie Rinehart,Violeta Sanchez,David Jee,Kornelia Polyak,Aleix Prat,Charles M. Perou,Carlos L. Arteaga,Rebecca S. Cook +12 more
TL;DR: It is reported here that ErbB3 loss in the luminal mammary epithelium of mice impaired Akt and MAPK signaling and reduced luminal cell proliferation and survival and ERBB3 mRNA expression levels were highest in luminal mammoth populations and lowest in basal cell/stem cell populations.
Journal ArticleDOI
Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis.
Jian Jiang,Carol E. Parker,Katherine A. Hoadley,Charles M. Perou,Gunnar Boysen,Christoph H. Borchers +5 more
TL;DR: A novel peptide‐based immuno tandem mass spectrometry (iMALDI) diagnostic assay for highly sensitive, highly specific, and quantitative analysis of EGFR, which has been applied to the detection of the EGFR peptide in three cell lines and in a tumor biopsy sample.
Journal ArticleDOI
Intratumoral Heterogeneity in a Trp53-Null Mouse Model of Human Breast Cancer
Mei Zhang,Anna Tsimelzon,Chi Hsuan Chang,Cheng Fan,Andrew Wolff,Charles M. Perou,Susan G. Hilsenbeck,Jeffrey M. Rosen +7 more
TL;DR: A unique subpopulation of tumor cells expressing mesenchymal-like markers is identified in a Trp53-null mouse model of basal-like breast cancer using fluorescence-activated cell sorting and microarray analysis and the existence of cross-talk between these "mesenchymic-like" cells and tumor-initiating cells is revealed.